Certain statements in this news release constitute “forward-looking statements” and/or “forward-looking information” under applicable securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Specific forward-looking statements in this document include, but are not limited to, statements relating to: the expected benefits of the Nualtis acquisition; the timing and outcome of regulatory submissions, approvals and related commercialization activities for Nualtis’ product pipeline; the growth of the markets in which Nualtis’ product pipeline operates; manufacturing validation, scale-up and commercialization readiness for Nualtis’ product pipeline; the anticipated revenue and other potential economic contributions associated with Nualtis’ product pipeline; the timing, number and nature of expected commercial product launches from Nualtis’ product pipeline; the development, regulatory pathway, commercialization and market opportunity for Nualtis’ human and animal health programs; the expectation of and timing to complete additional tranches of the Offering; the conversion, repayment and potential dilution associated with the Debentures; the timing to hold the Meeting to receive the Required Approvals; the Company’s ability to fund the Deferred Payment and maintain sufficient liquidity following completion of the Offering; and the plans, objectives, future outlook and financial position of the Company in general. All forward-looking statements are given pursuant to the “safe harbour” provisions of applicable securities legislation. Read More
FP Financial Post · Licensed syndication
COSCIENS ACQUIRES NUALTIS CORP.
TORONTO, ONTARIO, Sept. 10, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce the acquisition of Nualtis Corp. (“Nualtis”), a Montreal-based specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug…
